BRIEF-SoftBank-backed Tempus AI Targets Up To $6.10 Bln Valuation In US IPO-March 2024-www.financetom.com

BRIEF-SoftBank-backed Tempus AI Targets Up To $6.10 Bln Valuation In US IPO

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-SoftBank-backed Tempus AI Targets Up To $6.10 Bln Valuation In US IPO

Jun 5, 2024 4:38 AM

June 5 (Reuters) -

Tempus AI:

* TEMPUS AI INC SAYS CURRENTLY ESTIMATED IPO PRICE WILL BE

BETWEEN

$35.00 AND $37.00 PER SHARE - SEC FILING

* TEMPUS AI INC SEES IPO OF UP TO 11.1 MILLION CLASS A

SHARES OF

COMMON STOCK

* TEMPUS AI INC - CEO WILL BENEFICIALLY OWN 100% OF CO'S

OUTSTANDING CLASS B COMMON STOCK

* TEMPUS AI INC - CO'S CEO WILL BENEFICIALLY OWN ABOUT 65.3%

VOTING POWER OF CO'S OUTSTANDING CAPITAL STOCK IMMEDIATELY

FOLLOWING IPO

Source text for Eikon:

Previous page： EXPLAINER-What to know about bird flu in dairy cows and the risk to humans Next page： Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

EXPLAINER-What to know about bird flu in dairy cows and the risk to humans

May 30, 2024

(Adds details on third human case in paragraph 1, 2; updates throughout) By Julie Steenhuysen CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found...

Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar

May 30, 2024

03:46 PM EDT, 05/30/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) shares soared 137% in recent trading Thursday after the company shared results of ivonescimab meeting primary endpoint of progression-free survival to treat a type of lung cancer, beating Merck's ( MRK ) pembrolizumab. Results from the phase 3 trial showed that ivonescimab was statistically better at improving progression-free...

Canada to assess toxicity of compound found in oil sands tailings

May 30, 2024

May 30 (Reuters) - Canada has agreed to assess whether naphthenic acids found in northern Alberta's oil sands tailings ponds should be classed as toxic under federal law, a move that could pave the way for stricter regulations, environmental group Ecojustice said on Thursday. Tailings - a mix of water, clay, sand and trace metals - are a byproduct of...

HP Stock Makes Historic Move Higher: What's Going On?

May 30, 2024

HP Inc. ( HPQ ) experienced a historic stock surge Thursday afternoon, with shares climbing as much as 19% — the largest one-day gain since 1999 — following the release of its second-quarter financial results. What Happened: HP shares jumped after the tech giant reported net revenue of $12.8 billion, above the consensus estimate of $12.6 billion. Adjusted EPS rose...